Sir,

We appreciate the critical comments regarding our study conducted in 2011-2012[@ref1]. Our institute is a tertiary neuro care center and has a strict Hospital Infection Surveillance System which constantly monitors the MDR infections in the wards and Intensive Care Units. Also the percentages of drug-resistant isolates reported in our six-months study cannot be extrapolated to studies conducted in different hospitals receiving different types of specimen or studies conducted on particular infection sites. Studies quoted by the authors[@ref2][@ref3] provide data from multicenter studies and give an excellent overview of drug resistance scenario in the country. However, these studies were conducted in 2003[@ref3] and 2007[@ref2] and might not be relevant to the percentages of our study (6 months data from one hospital in 2011-2012)[@ref1].As part of routine laboratory screening of patients samples we performed the antibiotic sensitivity testing of the positive cultures as per CLSI guidelines[@ref4]. We considered those isolates to be MDR, that were resistant to the first and second line antibiotics - depending on the samples. As mentioned in our study[@ref1], only those isolates resistant to the following panel of antibiotics by disk diffusion method were considered for further analysis as NDM-1 producers are known to have additional mechanisms that make them resistant to several classes of antibiotics:In micrograms, ampicillin (10), amikacin (30), gentamicin (10), ciprofloxacin (5), ofloxacin (5), cefotaxime (30), ceftriaxone (30), ceftazidime (30), imipenem (10), cefoperazone-sulbactam (75/10), piperacillin-tazobactam (100/19), aztreonam (30), cefepime (30), tobramycin (19). A similar panel of antibiotics has been tested in the SMART study conducted from 2002-2011[@ref5].This is a tertiary care centre specializing in the central nervous system diseases and not having a considerable number of patients with other illnesses. Also, our hospital has a strict antibiotic policy and hospital infection surveillance system in place; which could be the main reason of our reduced rate of drug resistant bacteria as a whole.The carbapenem antibiotic that was screened using disk diffusion method was imipenem. All 74 isolates were resistant to imipenem by Kirby-Bauer disk diffusion method. The other carbapenem antibiotics-meropenem and ertapenem were checked through the Vitek 2 Compact 60 system. For certain isolates Vitek had suppressed certain carbapenems from analysis.The MIC values of meropenem (ME), ertapenem (ERT) and imipenem (IPM) for the six PCR-positive, variable carbapenem resistant isolates are as follows:The test that was performed for our study was the combined disk test or-imipenem - EDTA combined disk synergy test (CDST)[@ref6]. We regret the possible confusion caused due to the wrong naming.Table II has been referred to a particular section of the paper where all the calculations of percentages have been done according to the number of clinical specimens collected. The percentage of *bla*~*ndm*-1~ carrying *A. baumannii* (n = 4; 5.7%) was calculated among the number of samples studied (n = 70). It would be 20 per cent when calculated among the total MDR isolates of the same bacterial species. The same is applicable to *E. coli* also. In our study, 14.7 per cent of NDM-1 positive isolates were *E. coli* (5 PCR +ve *E. coli* /34 total PCR +ve isolates). Here the calculation was done based on the number of isolates. There were instances when more than one isolate were retrieved from one tracheal aspirate sample and hence \> 100 per cent value for the percentage of total number of isolates.For example, 45 isolates from 39 tracheal aspirate samples would give a percentage of 115.38 per cent. The Table was made in consultation with a biostatistician of the study centre.The susceptibility to tigecycline was assessed based on Vitek system report. The two isolates were *Providencia rettgeri* (MIC=2 µg/ml) and *Klebsiella pneumoniae* ssp *pneumoniae* (MIC ≥ 8 µg/ml), both isolated from tracheal samples. In a recently published article[@ref7] it has been stated that according to EUCAST breakpoints (<http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf>) P. rettgeri can be considered resistant to tigecycline with MIC = 2 mg/l.
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